The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome (Journal article)

Filippatos, T. D./ Gazi, I. F./ Liberopoulos, E. N./ Athyros, V. G./ Elisaf, M. S./ Tselepis, A. D./ Kiortsis, D. N.

BACKGROUND: Increased concentration of small dense LDL cholesterol (sdLDL-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are considered as emerging cardiovascular risk factors and are commonly encountered in subjects with metabolic syndrome (MetS). OBJECTIVE: The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS. METHODS: Patients (n=89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200mg/day (F group) or both (OF group) for 6 months. RESULTS: Significant reductions of sdLDL-C levels were observed in all treatment groups. Groups F and OF experienced a greater reduction in sdLDL-C levels (p<0.05) together with a greater increase in LDL particle diameter (p<0.05) compared with group O. Total plasma Lp-PLA(2) activity significantly decreased in all treatment groups. The reduction of Lp-PLA(2) was more pronounced with OF administration compared with each monotherapy (p<0.05). CONCLUSION: Orlistat and fenofibrate exhibited favorable effects on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients with MetS. Importantly, combination treatment had a more favorable effect on these risk factors.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: 1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood,Adult,Anti-Obesity Agents/pharmacology/therapeutic use,Cardiovascular Diseases/drug therapy/etiology,Cholesterol, LDL/*blood,Drug Therapy, Combination,Female,Fenofibrate/pharmacology/*therapeutic use,Humans,Hypolipidemic Agents/pharmacology/therapeutic use,Lactones/pharmacology/*therapeutic use,Male,Metabolic Syndrome X/drug therapy/etiology,Middle Aged,Obesity/complications/*drug therapy,Overweight,Phospholipases A2,Risk Factors
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/24553
ISSN: 0021-9150
Link: http://www.ncbi.nlm.nih.gov/pubmed/16911813
http://ac.els-cdn.com/S0021915006004084/1-s2.0-S0021915006004084-main.pdf?_tid=d29956a44a96251d298a203a6bbb2079&acdnat=1333531139_a7897d9d8d05921b4cdc9ffe783e74bc
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Filippatos-2007-The effect of orlist.pdf253.84 kBAdobe PDFView/Open    Request a copy


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24553
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.